SCHEMBL3558600

SCHEMBL3558600

CCCCc1ccc(N2CCN(c3ccc(C=O)cc3)C2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.51
FAAH O00519 1/20 0.42
MGLL Q99685 1/20 0.42
ALDH1A1 P00352 5/20 0.40
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 1/20 0.38
COMT P21964 1/20 0.38
HPGD P15428 2/20 0.37
HSD17B10 Q99714 1/20 0.37
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
GRIN2D O15399 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3553583 0.82 S1PR1 (0.56) S1PR1FAAHMGLLALDH1A1RAB9A
SCHEMBL219423 0.81 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL3550218 0.78 RAB9A (0.55) ALDH1A1TRIM24TRIM33RAB9AMEN1
SCHEMBL416529 0.76 RARB (0.56) ALDH1A1MEN1KMT2ASMN1; SMN2HPGD
SCHEMBL4454097 0.76 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL847304 0.76 ALDH1A1 (0.53) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL3555743 0.76 CYP4A11 (0.54) S1PR1ALDH1A1SMN1; SMN2THRATHRB
SCHEMBL2120077 0.74 ESR1 (0.57) MGLLALDH1A1MEN1KMT2AKDM4E
SCHEMBL11811560 0.74 ESR1 (0.57) MGLLALDH1A1MEN1KMT2AKDM4E
SCHEMBL20594193 0.74 ESR1 (0.57) MGLLALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof EPIX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
US-7790707-B2 S1P receptor modulating compounds and use thereof EPIX PHARMACEUTICALS INC. (US) 2010-09-07 US disclosed
EP-2010524-A2 S1P RECEPTOR MODULATING COMPOUNDS Epix Delaware, Inc. (US) 2009-01-07 EP disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
US-20080015177-A1 S1P receptor modulating compounds and use thereof AMGEN INC. 2008-01-17 US disclosed
WO-2007109330-A2 S1P RECEPTOR MODULATING COMPOUNDS EPIX DELAWARE, INC. (US) 2007-09-27 WO disclosed
WO-2007109330-A2 S1P RECEPTOR MODULATING COMPOUNDS EPIX DELAWARE, INC. (US) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015177-A1 S1P receptor modulating compounds and use thereof S1PR1, S1PR2, S1PR5 S1PR1 1/4885FAAH 394/4885MGLL 715/4885
US-20100317649-A1 S1P Receptor Modulating Compounds and Use Thereof S1PR1, S1PR2, S1PR5 S1PR1 1/4885FAAH 394/4885MGLL 715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.